Search peptides, terms, sources/
Melanocortin

PT-141 (Bremelanotide)

Also known as: Bremelanotide · Bremelanotide acetate

No UK marketing authorisation found; authorised in the US. Selective melanocortin-4 receptor agonist studied for low sexual desire in women.

UK status checked . Evidence last reviewed . By the PeptGuru editorial team (Astute Management).

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Strong evidence (level 4 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

1 finding at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. PT-141 is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials2 human trials

What is PT-141?

PT-141 (bremelanotide) is a synthetic peptide that selectively activates the melanocortin-4 receptor, studied for hypoactive sexual desire disorder in premenopausal women. No UK marketing authorisation was found, although it is authorised in the US. It has been studied in two large randomised placebo-controlled Phase 3 trials funded by its developer.

It acts on the hypothalamus. In the US it is approved under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women; it has no EU marketing authorisation either.

Class
Synthetic cyclic melanocortin-receptor agonist (MC4R-selective)
Origin
Fully synthetic
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does PT-141 work?

Bremelanotide is a melanocortin receptor agonist that is more selective for MC4R. This receptor sits in the hypothalamus, a brain area involved in sexual behaviour. Animal work links it to more dopamine release there, and a brain-imaging study in women found changes in areas linked to desire.

The mechanism in more detail

Bremelanotide is a high-affinity agonist at melanocortin receptors, with its clinically studied activity attributed specifically to the melanocortin-4 receptor (MC4R). MC4R is predominantly expressed in the medial preoptic area (mPOA) of the hypothalamus, a brain region involved in sexual behaviour. Animal studies indicate bremelanotide acts on MC4R located on mPOA neurons, increasing dopamine release, a neurotransmitter associated with sexual desire.

This animal pathway data is supported by a human neuroimaging study, in which MC4R agonism was associated with measurable changes in brain regions linked to sexual-desire processing in women with hypoactive sexual desire disorder (HSDD), compared with placebo. Together with two large Phase 3 trials showing improvements in sexual desire and desire-related distress, this provides a mechanistic bridge from receptor biology through to the clinical outcomes studied in the drug’s approved US indication.

Bremelanotide was developed from the same melanocortin research programme as Melanotan II, but was designed to be more selective for MC4R rather than acting non-selectively across melanocortin receptors. This selectivity underpins its distinct clinical development path: unlike Melanotan II, PT-141 progressed through formal Phase 3 trials and gained FDA approval for a specific indication in the US, though it has never been submitted for a marketing authorisation in the UK or EU.

Mechanisms and targets

Central/hypothalamic dopaminergic pathway modulationMelanocortin-4 receptor (MC4R) agonismSexual desire/arousal (central, not vascular, mechanism)MC4R (melanocortin 4 receptor)Medial preoptic area (mPOA)

Classification and structure

Names
PT-141 (Bremelanotide); Bremelanotide; Bremelanotide acetate
Class
Synthetic cyclic melanocortin-receptor agonist (MC4R-selective)
Origin
Fully synthetic
Routes used in the research
Subcutaneous injection in the pivotal Phase 3 RECONNECT trials. Early clinical studies tested intranasal and subcutaneous administration. This reflects study methodology, not a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

PT-141 has 2 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

2 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
01010

The RECONNECT Phase 3 trials Strong

Two identically designed Phase 3, randomised, double-blind, placebo-controlled, multicentre trials (RECONNECT-1 and RECONNECT-2), enrolling approximately 1,247 premenopausal women with hypoactive sexual desire disorder in total, found that self-administered subcutaneous bremelanotide produced statistically significant improvements in sexual desire and significant reductions in desire-related distress compared with placebo. The most common treatment-emergent adverse events were nausea, flushing and headache, mostly mild to moderate.

Study type
Human trial
Population
Human, premenopausal women with HSDD (DSM-IV-TR criteria), two trials, combined n approximately 1247, multicentre
Source
1 Kingsberg et al., 2019

Limitation: Both trials were funded and sponsored by the drug's developer, Palatin Technologies.

Limitations in full

Both trials were funded and sponsored by the drug's developer, Palatin Technologies. This is a conflict of interest readers should know about.

Neuroimaging in 31 women Limited

In a randomised, double-blind, placebo-controlled crossover study of 31 premenopausal women with hypoactive sexual desire disorder using functional neuroimaging, MC4R agonism (bremelanotide) was associated with changes in sexual brain processing (increased activation in brain regions associated with sexual desire) compared with placebo, providing a human-level mechanistic link between MC4R agonism and the clinical desire outcomes seen in the Phase 3 trials.

Study type
Human trial
Population
Human, premenopausal women with HSDD, n=31, randomised double-blind placebo-controlled crossover design
Source
2 Journal of Clinical Investigation

Limitation: Small sample (n=31) compared with the main efficacy trials; single study of this neuroimaging design, not yet replicated.

What safety findings have been reported?

1 safety finding is recorded for PT-141. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Vyleesi label adverse events

The FDA-approved label for Vyleesi (bremelanotide) reports nausea in approximately 40% of patients (requiring anti-emetic treatment in 13%, and leading to discontinuation in 8%); focal hyperpigmentation (face, gingiva, breasts) in approximately 1% of patients, generally reversible after discontinuation though resolution can take months, with higher risk in patients with darker skin and with more frequent dosing; and transient increases in blood pressure (mean +1.9 mmHg systolic / +1.7 mmHg diastolic daytime ambulatory blood pressure after 8 days of dosing), with around 1% of patients recording individual readings of 180/110 mmHg or higher. The label carries a caution regarding use in patients with uncontrolled hypertension or at cardiovascular risk.

Source
3 FDA, 2019

What is PT-141's UK regulatory status?

Marketing authorisation
No UK marketing authorisation. A search of the MHRA Products database for "bremelanotide" and for the US brand name "Vyleesi" returned no results (searched 14 November 2026).
Prescription status
Not applicable in the UK, no licensed product to classify. In the US, Vyleesi is a prescription-only self-injected product.
Medicine class
Not a licensed medicine in the UK.
MHRA position
No MHRA-specific enforcement notice, Yellow Card FOI data, or public assessment report for bremelanotide/PT-141 was located. As a melanocortin-receptor agonist, any UK product presented or sold with medicinal or therapeutic claims for human sexual-function use would fall to be regulated as an unauthorised medicinal product under the Human Medicines Regulations 2012.
Authorised use
None in the UK. In the US: FDA-approved, 21 June 2019, for acquired, generalised hypoactive sexual desire disorder in premenopausal women. This is a US-specific approval and does not extend to the UK.
Research use
No UK-authorised bremelanotide product exists. Bremelanotide (Vyleesi) is authorised in the US.
Other restrictions
No UK-specific regulatory document naming bremelanotide was found. The absence of a UK licence is recorded here as a search result, not as a regulatory decision.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. PT-141 is recorded as not licensed in the UK (checked 14 November 2026).

References

4 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Kingsberg SA, Clayton AH, Portman D, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder, Two Randomized Phase 3 Trials. Obstetrics & GynecologyHuman clinical trial, RCT · DOI 10.1097/AOG.0000000000003500 · PMID 31599840 · Original ↗
  2. Journal of Clinical Investigation Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. Journal of Clinical Investigation (JCI)Human clinical trial, RCT · Original ↗
  3. FDA (2019). VYLEESI (bremelanotide injection), Prescribing Information / FDA approval documentation (NDA 210557). U.S. Food and Drug Administration (FDA) · Original ↗
  4. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: search for bremelanotide and Vyleesi. MHRA Products database · Original ↗

Questions about PT-141

What is PT-141?

PT-141 (bremelanotide) is a synthetic peptide that selectively activates the melanocortin-4 receptor, studied for hypoactive sexual desire disorder in premenopausal women. No UK marketing authorisation was found, although it is authorised in the US. It has been studied in two large randomised placebo-controlled Phase 3 trials funded by its developer. Read what it is.

Is PT-141 licensed in the UK?

PeptGuru records PT-141's UK status as: Not licensed in the UK. No UK marketing authorisation. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on PT-141 show?

PeptGuru records 2 research findings for PT-141: 2 from human trials. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for PT-141?

1 safety finding is recorded, including: vyleesi label adverse events. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for PT-141?

All 4 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Regulatory update · UK status now cites an MHRA Products database search (no UK authorisation found). An unsourced statement about the reason was removed.

How findings are graded: the grading method. All changes.

  • KisspeptinMetastin

    Natural reproductive hormone studied in UK trials for low sexual desire and IVF egg maturation. No UK marketing authorisation identified.

    Hormonal signallingHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • Oxytocin

    Natural hormone licensed in the UK for obstetric use; studied separately for social cognition, with mostly negative trial results.

    Hormonal signallingHuman trialsEvidence reviewed
    LimitedLicensed for a different use
  • Setmelanotide

    Synthetic peptide that activates the MC4 receptor, studied in rare forms of obesity. UK prescription-only medicine for three rare conditions; trials were small and do not cover common obesity.

    MelanocortinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine
  • Afamelanotide

    Synthetic alpha-MSH analogue studied in erythropoietic protoporphyria (EPP). Licensed in the UK for adults with EPP; not recommended for routine NHS use. Not the same as Melanotan II.

    MelanocortinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine

Compare PT-141 with Kisspeptin

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.